Regulus Therapeutics Inc. (NASDAQ:RGLS - Get Free Report)'s stock price crossed above its two hundred day moving average during trading on Monday . The stock has a two hundred day moving average of $2.83 and traded as high as $8.35. Regulus Therapeutics shares last traded at $8.30, with a volume of 1,483,526 shares traded.
Wall Street Analysts Forecast Growth
RGLS has been the subject of several analyst reports. Wall Street Zen initiated coverage on Regulus Therapeutics in a research report on Sunday, May 18th. They set a "sell" rating for the company. Wells Fargo & Company reaffirmed an "equal weight" rating and issued a $9.00 target price on shares of Regulus Therapeutics in a research report on Thursday, May 1st. Leerink Partners reissued a "market perform" rating and issued a $7.00 price objective on shares of Regulus Therapeutics in a research note on Wednesday, April 30th. Canaccord Genuity Group reaffirmed a "hold" rating and set a $11.00 target price (down previously from $28.00) on shares of Regulus Therapeutics in a research report on Wednesday, April 30th. Finally, Jones Trading reaffirmed a "hold" rating and set a $7.00 target price (down previously from $8.00) on shares of Regulus Therapeutics in a research report on Wednesday, April 30th. One analyst has rated the stock with a sell rating, five have assigned a hold rating and two have assigned a buy rating to the company's stock. According to data from MarketBeat.com, the company has a consensus rating of "Hold" and a consensus price target of $8.50.
Get Our Latest Stock Report on RGLS
Regulus Therapeutics Trading Up 0.4%
The business has a 50-day moving average price of $5.87 and a 200 day moving average price of $2.95. The stock has a market cap of $561.49 million, a PE ratio of -7.58 and a beta of 0.35.
Regulus Therapeutics (NASDAQ:RGLS - Get Free Report) last announced its quarterly earnings results on Thursday, May 8th. The biopharmaceutical company reported ($0.15) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.29) by $0.14. On average, equities analysts predict that Regulus Therapeutics Inc. will post -0.88 earnings per share for the current year.
Insider Buying and Selling
In other Regulus Therapeutics news, insider Preston Klassen bought 12,000 shares of the firm's stock in a transaction on Tuesday, June 3rd. The shares were acquired at an average cost of $7.99 per share, for a total transaction of $95,880.00. Following the purchase, the insider now directly owns 48,055 shares of the company's stock, valued at $383,959.45. The trade was a 33.28% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 4.35% of the stock is currently owned by company insiders.
Institutional Investors Weigh In On Regulus Therapeutics
A number of large investors have recently added to or reduced their stakes in the company. Barclays PLC grew its position in Regulus Therapeutics by 13.9% during the fourth quarter. Barclays PLC now owns 96,247 shares of the biopharmaceutical company's stock valued at $152,000 after acquiring an additional 11,770 shares during the last quarter. JPMorgan Chase & Co. boosted its stake in shares of Regulus Therapeutics by 141.2% in the 4th quarter. JPMorgan Chase & Co. now owns 190,457 shares of the biopharmaceutical company's stock valued at $301,000 after purchasing an additional 111,485 shares in the last quarter. Millennium Management LLC grew its holdings in shares of Regulus Therapeutics by 69.7% during the 4th quarter. Millennium Management LLC now owns 2,192,158 shares of the biopharmaceutical company's stock valued at $3,464,000 after purchasing an additional 900,743 shares during the last quarter. Velan Capital Investment Management LP purchased a new position in Regulus Therapeutics in the 4th quarter worth $111,000. Finally, Octagon Capital Advisors LP raised its position in Regulus Therapeutics by 13.7% in the 4th quarter. Octagon Capital Advisors LP now owns 4,848,802 shares of the biopharmaceutical company's stock worth $7,661,000 after purchasing an additional 585,101 shares during the period. Hedge funds and other institutional investors own 92.38% of the company's stock.
Regulus Therapeutics Company Profile
(
Get Free Report)
Regulus Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease.
Featured Articles
Before you consider Regulus Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Regulus Therapeutics wasn't on the list.
While Regulus Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.